Cell and gene therapy venture capital and public funding deal count vs Alzheimer's disease drug trial starts

In 2023, cell and gene therapy venture capital and public funding deal count worldwide stood at 96, against 58 for alzheimer's disease drug trial starts.

Change the pair

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Cell and gene therapy venture capital and public funding deal count and Alzheimer's disease drug trial starts

Unit: count · 9 observations

2 series · one axis

View the underlying data

Cell and gene therapy venture capital and public funding deal count and Alzheimer's disease drug trial starts: Global
Indicator	Period	Type	Value
Cell and gene therapy venture capital and public funding deal count	2023	Actual	96
Cell and gene therapy venture capital and public funding deal count	2022	Actual	97
Cell and gene therapy venture capital and public funding deal count	2021	Actual	127
Alzheimer's disease drug trial starts	2025	Actual	78
Alzheimer's disease drug trial starts	2024	Actual	71
Alzheimer's disease drug trial starts	2023	Actual	58
Alzheimer's disease drug trial starts	2022	Actual	81
Alzheimer's disease drug trial starts	2021	Actual	87
Alzheimer's disease drug trial starts	2020	Actual	66

Source: IQVIA, ClinicalTrials.gov · CC BY 4.0 · Cell and gene therapy venture capital and public funding deal count · Alzheimer's disease drug trial starts

Shared periods

Side by side

3 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period	Cell and gene therapy venture capital and public funding deal count	Alzheimer's disease drug trial starts
2021	127 IQVIA	87 ClinicalTrials.gov
2022	97 IQVIA	81 ClinicalTrials.gov
2023	96 IQVIA	58 ClinicalTrials.gov

Provenance

Where these numbers come from